[
    {
        "molecule_name": "Immunoglobulin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In another embodiment, an antibody competes for binding to pro/latent-Myostatin with an equilibrium dissociation constant, Kd, between the antibody and pro/latent-Myostatin of is less than 10<sup>−6 </sup>M.\nIn other embodiments, said antibody's Kd is in a range of 10<sup>−11 </sup>M to 10<sup>−6 </sup>M.\nA further aspect of the disclosure includes an antibody that specifically binds pro/latent-Myostatin and that inhibits proteolytic formation of mature myostatin by a tolloid protease with an IC50 of less than 1 μM."
    },
    {
        "molecule_name": "Immunoglobulin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10^−11 to 10^−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In another embodiment, an antibody competes for binding to pro/latent-Myostatin with an equilibrium dissociation constant, Kd, between the antibody and pro/latent-Myostatin of is less than 10<sup>−6 </sup>M.\nIn other embodiments, said antibody's Kd is in a range of 10<sup>−11 </sup>M to 10<sup>−6 </sup>M.\nA further aspect of the disclosure includes an antibody that specifically binds pro/latent-Myostatin and that inhibits proteolytic formation of mature myostatin by a tolloid protease with an IC50 of less than 1 μM."
    },
    {
        "molecule_name": "Immunoglobulin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "<1",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "In another embodiment, an antibody competes for binding to pro/latent-Myostatin with an equilibrium dissociation constant, Kd, between the antibody and pro/latent-Myostatin of is less than 10<sup>−6 </sup>M.\nIn other embodiments, said antibody's Kd is in a range of 10<sup>−11 </sup>M to 10<sup>−6 </sup>M.\nA further aspect of the disclosure includes an antibody that specifically binds pro/latent-Myostatin and that inhibits proteolytic formation of mature myostatin by a tolloid protease with an IC50 of less than 1 μM."
    },
    {
        "molecule_name": "Myostatin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, an anti-pro/latent-Myostatin antibodies of the disclosure can bind to pro/latent-Myostatin with relatively high affinity, e.g., with a Kd less than10<sup>−6 </sup>M, 10<sup>−7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−10 </sup>M, 10<sup>−11 </sup>M or lower.\n* For example, anti-pro/latent-Myostatin antibodies can bind to pro/latent-Myostatin with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM.\n* The disclosure also includes antibodies or antigen binding fragments that compete with any of the antibodies described herein for binding to pro/latent-Myostatin and that have an affinity of 50 nM or lower (e.g., 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower)."
    },
    {
        "molecule_name": "Myostatin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, an anti-pro/latent-Myostatin antibodies of the disclosure can bind to pro/latent-Myostatin with relatively high affinity, e.g., with a Kd less than10<sup>−6 </sup>M, 10<sup>−7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−10 </sup>M, 10<sup>−11 </sup>M or lower.\n* For example, anti-pro/latent-Myostatin antibodies can bind to pro/latent-Myostatin with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM.\n* The disclosure also includes antibodies or antigen binding fragments that compete with any of the antibodies described herein for binding to pro/latent-Myostatin and that have an affinity of 50 nM or lower (e.g., 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower)."
    },
    {
        "molecule_name": "Myostatin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, an anti-pro/latent-Myostatin antibodies of the disclosure can bind to pro/latent-Myostatin with relatively high affinity, e.g., with a Kd less than10<sup>−6 </sup>M, 10<sup>−7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−10 </sup>M, 10<sup>−11 </sup>M or lower.\n* For example, anti-pro/latent-Myostatin antibodies can bind to pro/latent-Myostatin with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM.\n* The disclosure also includes antibodies or antigen binding fragments that compete with any of the antibodies described herein for binding to pro/latent-Myostatin and that have an affinity of 50 nM or lower (e.g., 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower)."
    },
    {
        "molecule_name": "Myostatin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, an anti-pro/latent-Myostatin antibodies of the disclosure can bind to pro/latent-Myostatin with relatively high affinity, e.g., with a Kd less than10<sup>−6 </sup>M, 10<sup>−7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−10 </sup>M, 10<sup>−11 </sup>M or lower.\n* For example, anti-pro/latent-Myostatin antibodies can bind to pro/latent-Myostatin with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM.\n* The disclosure also includes antibodies or antigen binding fragments that compete with any of the antibodies described herein for binding to pro/latent-Myostatin and that have an affinity of 50 nM or lower (e.g., 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower)."
    },
    {
        "molecule_name": "Myostatin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, an anti-pro/latent-Myostatin antibodies of the disclosure can bind to pro/latent-Myostatin with relatively high affinity, e.g., with a Kd less than10<sup>−6 </sup>M, 10<sup>−7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−10 </sup>M, 10<sup>−11 </sup>M or lower.\n* For example, anti-pro/latent-Myostatin antibodies can bind to pro/latent-Myostatin with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM.\n* The disclosure also includes antibodies or antigen binding fragments that compete with any of the antibodies described herein for binding to pro/latent-Myostatin and that have an affinity of 50 nM or lower (e.g., 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower)."
    },
    {
        "molecule_name": "Myostatin",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "<10^−11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, an anti-pro/latent-Myostatin antibodies of the disclosure can bind to pro/latent-Myostatin with relatively high affinity, e.g., with a Kd less than10<sup>−6 </sup>M, 10<sup>−7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−10 </sup>M, 10<sup>−11 </sup>M or lower.\n* For example, anti-pro/latent-Myostatin antibodies can bind to pro/latent-Myostatin with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM.\n* The disclosure also includes antibodies or antigen binding fragments that compete with any of the antibodies described herein for binding to pro/latent-Myostatin and that have an affinity of 50 nM or lower (e.g., 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower)."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−3 to 10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−3 to 10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−3 to 10−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−3 to 10−5",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−3 to 10−4",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−4 to 10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−4 to 10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−4 to 10−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−4 to 10−5",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−5 to 10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−5 to 10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−5 to 10−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−6 to 10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−6 to 10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "sweeping antibody",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "10−7 to 10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In some embodiments, the Fc portion of a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from 10<sup>−3 </sup>M to 10<sup>−8 </sup>M.\nIn some embodiments, a sweeping antibody binds to FcRn at a pH of 7.4 with a Kd ranging from10<sup>−3 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−3 </sup>M to 10<sup>−5</sup>M, from 10<sup>−3 </sup>M to 10<sup>−4 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−4 </sup>M to 10<sup>−6</sup>M, from 10<sup>−4 </sup>M to 10<sup>−5 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−7 </sup>M, from 10<sup>−5 </sup>M to 10<sup>−6 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−8 </sup>M, from 10<sup>−6 </sup>M to 10<sup>−7 </sup>M, or from 10<sup>−7 </sup>M to 10<sup>−8</sup>M."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−3",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−4",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−5",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−6",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−1",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Immunoglobulins",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "10−11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−3 </sup>M, 10<sup>−4 </sup>M, 10<sup>−5 </sup>M, 10<sup>−6</sup>m, 10<sup>−7 </sup>M, 10<sup>−8 </sup>M when the pH is between 4.0 and 6.5.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin ranging from 10<sup>−6 </sup>M, 10<sup>-7 </sup>M, 10<sup>−8</sup>M, 10<sup>−9</sup>M, 10<sup>−1</sup>° M, 10<sup>−11 </sup>M when the pH is between 7.0 and 7.4.\nIn some embodiments, the antibodies provided herein have a Kd of binding to pro/latent-Myostatin that is at least 2 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold, at least 5000 fold, or at least 10000 fold greater at a pH between 4.0 and 6.5 as compared to a pH between 7.0 and 7.4."
    },
    {
        "molecule_name": "Ab2",
        "protein_target_name": "human pro- and latent- myostatin",
        "binding_metric": "Kd",
        "value": "3420",
        "unit": "pM",
        "is_logarithmic": false,
        "raw_mentions": "Ab2 is a fully human anti-pro/latent-Myostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent- myostatin with high affinity (Kd=3420 pM by ForteBio BLI).\nThe antibody is capable of inhibiting the proteolytic activation of pro/latent-Myostatin with IC50 values in the 0.5 micromolar range (which is at or near the limit of the assay)."
    },
    {
        "molecule_name": "Ab2",
        "protein_target_name": "pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "0.5",
        "unit": "micromolar",
        "is_logarithmic": false,
        "raw_mentions": "Ab2 is a fully human anti-pro/latent-Myostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent- myostatin with high affinity (Kd=3420 pM by ForteBio BLI).\nThe antibody is capable of inhibiting the proteolytic activation of pro/latent-Myostatin with IC50 values in the 0.5 micromolar range (which is at or near the limit of the assay)."
    },
    {
        "molecule_name": "Ab111",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "1.5",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab111",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "0.99",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab111",
        "protein_target_name": "murine pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "1.46",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab728",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "0.98",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab728",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "1.68",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab728",
        "protein_target_name": "murine pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "1.28",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab8",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "0.56",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab8",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "6.03",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab8",
        "protein_target_name": "murine pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "1.39",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab922",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "1.21",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab922",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "2.16",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab922",
        "protein_target_name": "murine pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "1.98",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab100",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "Kd",
        "value": "0.30",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab100",
        "protein_target_name": "human pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "0.77",
        "unit": "μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    },
    {
        "molecule_name": "Ab100",
        "protein_target_name": "murine pro/latent-Myostatin",
        "binding_metric": "IC50",
        "value": "ND",
        "unit": null,
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAb111 has a Kd of 1.5 μM and IC50 of 0.99 μM and 1.46 μM for human and murine pro/latent-Myostatin, respectively.\nAb728 has a Kd of 0.98 μM and IC50 of 1.68 μM and 1.28 μM for human and murine pro/latent-Myostatin, respectively.\nAb8 has a Kd of 0.56 μM and IC50 of 6.03 μM and 1.39 μM for human and murine pro/latent-Myostatin, respectively.\nAb922 has a Kd of 1.21 μM and IC50 of 2.16 μM and 1.98 μM for human and murine pro/latent-Myostatin, respectively.\nAb100 has a Kd of 0.30 μM and IC50 of 0.77 μM and ND for human and murine pro/latent-Myostatin, respectively.\n\nNote: These sentences are reconstructed from the table data to provide a clear and readable format. The original table rows are:\n\nAb111, 1.5, 0.99, 1.46\nAb728, 0.98, 1.68, 1.28\nAb8, 0.56, 6.03, 1.39\nAb922, 1.21, 2.16, 1.98\nAb100, 0.30, 0.77, ND"
    }
]